Our Website Uses Cookies 

We and the third parties that provide content, functionality, or business services on our website may use cookies to collect information about your browsing activities in order to provide you with more relevant content and promotional materials, on and off the website, and help us understand your interests and improve the website.

For more information, please contact us or consult our Privacy Notice.

Your binder contains too many pages, the maximum is 40.

We are unable to add this page to your binder, please try again later.

This page has been added to your binder.

Covington Advises Consort Medical on Aesica Holdco Acquisition and related £260 million financing

October 10, 2014

LONDON, 10 October, 2014 — Covington & Burling is advising Consort Medical plc on the acquisition of Aesica Holdco Limited and its operating subsidiaries from private equity fund Silverfleet Capital and its management shareholders for a total consideration of approximately £230 million. Covington is also advising Consort Medical plc on the £98.9 million Rights Issue and New Debt Facility of £160 million to be used, inter alia, to fund the acquisition.

Consort Medical plc is an international healthcare company focused primarily on developing and manufacturing disposable medical devices for drug delivery, particularly focused on respiratory, auto-injectors, nasal, nicotine delivery and point of care diagnostics. The company is listed and traded on the premium segment of the UK Listing Authority official list and on the London Stock Exchange’s main market. Aesica is one of Europe’s leading pharmaceutical contract development and manufacturing organisations.

The London and Brussels-based Covington team is being led by partner Paul Claydon, and includes partners James Gubbins, Gregor Frizzell, Simon Amies, Kristian Wiggert and Miranda Cole, of counsel Guy Dingley and associates Sarah Hoult, Andrew Dalton, Alex Clarke, Simon Williams and Kristian Shearsby.

Share this article: